Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IGC-AD1

Other · developed by IGC Pharma, LLC

Phase 2 Most advanced trial

IGC Developer

2 Registered trials

What is IGC-AD1?

IGC-AD1 is an investigational drug studied in Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden.

At a glance

Also known as: IGC AD1
Drug type: Other
Therapy area: Neurology
Developer: IGC Pharma, LLC (IGC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05543681	Phase 2	Alzheimer Disease	Active not recruiting	IGC
NCT04749563	Phase 1	Dementia of Alzheimer Type	Completed	IGC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AggressionAgitation,PsychomotorAlzheimer DiseaseCare Giving BurdenNPSDementia of Alzheimer Type

Sources

ClinicalTrials.gov NCT05543681

Updated Oct 3, 2026. Something wrong or missing? Report it on the IGC page.

Follow IGC, the company behind IGC-AD1

See IGC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IGC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z